Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Long Receptor Residence Time of C26 Contributes to Super Agonist Activity at the Human β2 Adrenoceptor.

Rosethorne EM, Bradley ME, Gherbi K, Sykes DA, Sattikar A, Wright JD, Renard E, Trifilieff A, Fairhurst RA, Charlton SJ.

Mol Pharmacol. 2016 Apr;89(4):467-75. doi: 10.1124/mol.115.101253. Epub 2016 Jan 15.

PMID:
26772612
2.

Discovery and Optimization of 4-(8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic Acid, an Improved PDE4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease (COPD).

Press NJ, Taylor RJ, Fullerton JD, Tranter P, McCarthy C, Keller TH, Arnold N, Beer D, Brown L, Cheung R, Christie J, Denholm A, Haberthuer S, Hatto JD, Keenan M, Mercer MK, Oakman H, Sahri H, Tuffnell AR, Tweed M, Trifilieff A.

J Med Chem. 2015 Sep 10;58(17):6747-52. doi: 10.1021/acs.jmedchem.5b00902. Epub 2015 Aug 28.

PMID:
26288344
3.

Comparing the cardiovascular therapeutic indices of glycopyrronium and tiotropium in an integrated rat pharmacokinetic, pharmacodynamic and safety model.

Trifilieff A, Ethell BT, Sykes DA, Watson KJ, Collingwood S, Charlton SJ, Kent TC.

Toxicol Appl Pharmacol. 2015 Aug 15;287(1):9-16. doi: 10.1016/j.taap.2015.05.012. Epub 2015 May 27.

PMID:
26026369
4.

The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist.

Arnold N, Beattie D, Bradley M, Brearley A, Brown L, Charlton SJ, Fairhurst RA, Farr D, Fozard J, Fullerton J, Gosling M, Hatto J, Janus D, Jones D, Jordan L, Lewis C, Maas J, McCarthy C, Mercer M, Oakman H, Press N, Profit R, Schuerch F, Sykes D, Taylor RJ, Trifilieff A, Tuffnell A.

Bioorg Med Chem Lett. 2014 Sep 1;24(17):4341-7. doi: 10.1016/j.bmcl.2014.06.014. Epub 2014 Jun 26.

PMID:
25065493
5.

An investigation into the structure-activity relationships associated with the systematic modification of the β(2)-adrenoceptor agonist indacaterol.

Beattie D, Beer D, Bradley ME, Bruce I, Charlton SJ, Cuenoud BM, Fairhurst RA, Farr D, Fozard JR, Janus D, Rosethorne EM, Sandham DA, Sykes DA, Trifilieff A, Turner KL, Wissler E.

Bioorg Med Chem Lett. 2012 Oct 1;22(19):6280-5. doi: 10.1016/j.bmcl.2012.07.096. Epub 2012 Aug 4.

PMID:
22932315
6.

Solubility-driven optimization of phosphodiesterase-4 inhibitors leading to a clinical candidate.

Press NJ, Taylor RJ, Fullerton JD, Tranter P, McCarthy C, Keller TH, Arnold N, Beer D, Brown L, Cheung R, Christie J, Denholm A, Haberthuer S, Hatto JD, Keenan M, Mercer MK, Oakman H, Sahri H, Tuffnell AR, Tweed M, Tyler JW, Wagner T, Fozard JR, Trifilieff A.

J Med Chem. 2012 Sep 13;55(17):7472-9. doi: 10.1021/jm300459a. Epub 2012 Aug 30.

PMID:
22889281
7.

The Influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium.

Sykes DA, Dowling MR, Leighton-Davies J, Kent TC, Fawcett L, Renard E, Trifilieff A, Charlton SJ.

J Pharmacol Exp Ther. 2012 Nov;343(2):520-8. doi: 10.1124/jpet.112.194456. Epub 2012 Aug 1.

PMID:
22854200
8.

Sphingosine-1-phosphate-induced airway hyper-reactivity in rodents is mediated by the sphingosine-1-phosphate type 3 receptor.

Trifilieff A, Fozard JR.

J Pharmacol Exp Ther. 2012 Aug;342(2):399-406. doi: 10.1124/jpet.112.191585. Epub 2012 May 8.

PMID:
22570366
9.

The ion channel transient receptor potential melastatin-2 does not play a role in inflammatory mouse models of chronic obstructive pulmonary diseases.

Hardaker L, Bahra P, de Billy BC, Freeman M, Kupfer N, Wyss D, Trifilieff A.

Respir Res. 2012 Apr 4;13:30. doi: 10.1186/1465-9921-13-30.

10.

A pharmacogenetic study of ADRB2 polymorphisms and indacaterol response in COPD patients.

Yelensky R, Li Y, Lewitzky S, Leroy E, Hurwitz C, Rodman D, Trifilieff A, Paulding CA.

Pharmacogenomics J. 2012 Dec;12(6):484-8. doi: 10.1038/tpj.2011.54. Epub 2011 Dec 13.

PMID:
22158330
11.

The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.

Baur F, Beattie D, Beer D, Bentley D, Bradley M, Bruce I, Charlton SJ, Cuenoud B, Ernst R, Fairhurst RA, Faller B, Farr D, Keller T, Fozard JR, Fullerton J, Garman S, Hatto J, Hayden C, He H, Howes C, Janus D, Jiang Z, Lewis C, Loeuillet-Ritzler F, Moser H, Reilly J, Steward A, Sykes D, Tedaldi L, Trifilieff A, Tweed M, Watson S, Wissler E, Wyss D.

J Med Chem. 2010 May 13;53(9):3675-84. doi: 10.1021/jm100068m.

PMID:
20402514
12.

Activation of the lung S1P(1) receptor reduces allergen-induced plasma leakage in mice.

Blé FX, Cannet C, Zurbruegg S, Gérard C, Frossard N, Beckmann N, Trifilieff A.

Br J Pharmacol. 2009 Nov;158(5):1295-301. doi: 10.1111/j.1476-5381.2009.00391.x. Epub 2009 Sep 25.

13.

Role of sphingosine-1-phosphate (S1P) and the S1P(2) receptor in allergen-induced, mast cell-dependent contraction of rat lung parenchymal strips.

Trifilieff A, Baur F, Fozard JR.

Naunyn Schmiedebergs Arch Pharmacol. 2009 Oct;380(4):303-9. doi: 10.1007/s00210-009-0438-4. Epub 2009 Jul 28.

PMID:
19636535
14.

Essential role of phosphoinositide 3-kinase gamma in eosinophil chemotaxis within acute pulmonary inflammation.

Thomas M, Edwards MJ, Sawicka E, Duggan N, Hirsch E, Wymann MP, Owen C, Trifilieff A, Walker C, Westwick J, Finan P.

Immunology. 2009 Mar;126(3):413-22. doi: 10.1111/j.1365-2567.2008.02908.x. Epub 2008 Aug 27.

15.

Allergen-induced lung inflammation in actively sensitized mice assessed with MR imaging.

Blé FX, Cannet C, Zurbruegg S, Karmouty-Quintana H, Bergmann R, Frossard N, Trifilieff A, Beckmann N.

Radiology. 2008 Sep;248(3):834-43. doi: 10.1148/radiol.2482071452. Epub 2008 Jul 22.

PMID:
18647843
16.

Lung MRI for experimental drug research.

Beckmann N, Cannet C, Karmouty-Quintana H, Tigani B, Zurbruegg S, Blé FX, Crémillieux Y, Trifilieff A.

Eur J Radiol. 2007 Dec;64(3):381-96. Epub 2007 Oct 10. Review.

PMID:
17931813
17.

Pharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices.

Sturton RG, Trifilieff A, Nicholson AG, Barnes PJ.

J Pharmacol Exp Ther. 2008 Jan;324(1):270-5. Epub 2007 Oct 4.

PMID:
17916760
18.

Effects of PKF242-484 and PKF241-466, novel dual inhibitors of TNF-alpha converting enzyme and matrix metalloproteinases, in a model of intestinal reperfusion injury in mice.

Souza DG, Ferreira FL, Fagundes CT, Amaral FA, Vieira AT, Lisboa RA, Andrade MV, Trifilieff A, Teixeira MM.

Eur J Pharmacol. 2007 Sep 24;571(1):72-80. Epub 2007 Jun 12.

PMID:
17619015
19.

Synergistic effect of formoterol and mometasone in a mouse model of allergic lung inflammation.

Wyss D, Bonneau O, Trifilieff A.

Br J Pharmacol. 2007 Sep;152(1):83-90. Epub 2007 Jul 9.

20.

Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi.

Naline E, Trifilieff A, Fairhurst RA, Advenier C, Molimard M.

Eur Respir J. 2007 Mar;29(3):575-81. Epub 2006 Nov 29.

21.

In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action.

Battram C, Charlton SJ, Cuenoud B, Dowling MR, Fairhurst RA, Farr D, Fozard JR, Leighton-Davies JR, Lewis CA, McEvoy L, Turner RJ, Trifilieff A.

J Pharmacol Exp Ther. 2006 May;317(2):762-70. Epub 2006 Jan 24.

PMID:
16434564
22.

Effect of adenosine A2A receptor activation in murine models of respiratory disorders.

Bonneau O, Wyss D, Ferretti S, Blaydon C, Stevenson CS, Trifilieff A.

Am J Physiol Lung Cell Mol Physiol. 2006 May;290(5):L1036-43. Epub 2005 Dec 9.

23.
24.

Airway inflammation: chemokine-induced neutrophilia and the class I phosphoinositide 3-kinases.

Thomas MJ, Smith A, Head DH, Milne L, Nicholls A, Pearce W, Vanhaesebroeck B, Wymann MP, Hirsch E, Trifilieff A, Walker C, Finan P, Westwick J.

Eur J Immunol. 2005 Apr;35(4):1283-91.

25.
27.

Inhibition of Th1- and Th2-mediated airway inflammation by the sphingosine 1-phosphate receptor agonist FTY720.

Sawicka E, Zuany-Amorim C, Manlius C, Trifilieff A, Brinkmann V, Kemeny DM, Walker C.

J Immunol. 2003 Dec 1;171(11):6206-14.

28.

Differential DNA synthesis in response to activation of protease-activated receptors on cultured guinea-pig tracheal smooth muscle cells.

Corteling R, Bonneau O, Ferretti S, Ferretti M, Trifilieff A.

Naunyn Schmiedebergs Arch Pharmacol. 2003 Jul;368(1):10-6. Epub 2003 Jun 18.

PMID:
12819855
29.
30.

Involvement of CCR3-reactive chemokines in eosinophil survival.

Shinagawa K, Trifilieff A, Anderson GP.

Int Arch Allergy Immunol. 2003 Feb;130(2):150-7.

PMID:
12673069
31.
32.

The Th2 cell cytokines IL-4 and IL-13 regulate found in inflammatory zone 1/resistin-like molecule alpha gene expression by a STAT6 and CCAAT/enhancer-binding protein-dependent mechanism.

Stütz AM, Pickart LA, Trifilieff A, Baumruker T, Prieschl-Strassmayr E, Woisetschläger M.

J Immunol. 2003 Feb 15;170(4):1789-96.

33.

Phosphoinositide 3-kinase gamma: a key modulator in inflammation and allergy.

Wymann MP, Björklöf K, Calvez R, Finan P, Thomast M, Trifilieff A, Barbier M, Altruda F, Hirsch E, Laffargue M.

Biochem Soc Trans. 2003 Feb;31(Pt 1):275-80. Review.

PMID:
12546701
34.

In vivo and in vitro effects of SAR 943, a rapamycin analogue, on airway inflammation and remodeling.

Fujitani Y, Trifilieff A.

Am J Respir Crit Care Med. 2003 Jan 15;167(2):193-8. Epub 2002 Oct 24.

PMID:
12406821
35.

ONO-6818 Cortech/Ono.

Trifilieff A.

Curr Opin Investig Drugs. 2002 Aug;3(8):1161-4. Review.

PMID:
12211408
36.

Long-term protective and antigen-specific effect of heat-killed Mycobacterium vaccae in a murine model of allergic pulmonary inflammation.

Zuany-Amorim C, Manlius C, Trifilieff A, Brunet LR, Rook G, Bowen G, Pay G, Walker C.

J Immunol. 2002 Aug 1;169(3):1492-9.

37.
38.

Phosphoinositide 3-kinase gamma is an essential amplifier of mast cell function.

Laffargue M, Calvez R, Finan P, Trifilieff A, Barbier M, Altruda F, Hirsch E, Wymann MP.

Immunity. 2002 Mar;16(3):441-51.

40.

In vivo models of lung neutrophil activation. Comparison of mice and hamsters.

Corteling R, Wyss D, Trifilieff A.

BMC Pharmacol. 2002;2:1. Epub 2002 Jan 10.

41.

IL-5 deficiency abolishes aspects of airway remodelling in a murine model of lung inflammation.

Trifilieff A, Fujitani Y, Coyle AJ, Kopf M, Bertrand C.

Clin Exp Allergy. 2001 Jun;31(6):934-42.

PMID:
11422160
42.

Time course of inflammatory and remodeling events in a murine model of asthma: effect of steroid treatment.

Trifilieff A, El-Hashim A, Bertrand C.

Am J Physiol Lung Cell Mol Physiol. 2000 Dec;279(6):L1120-8.

43.

Abrogation of lung inflammation in sensitized Stat6-deficient mice is dependent on the allergen inhalation procedure.

Trifilieff A, El-Hasim A, Corteling R, Owen CE.

Br J Pharmacol. 2000 Aug;130(7):1581-8.

44.

Inducible nitric oxide synthase inhibitors suppress airway inflammation in mice through down-regulation of chemokine expression.

Trifilieff A, Fujitani Y, Mentz F, Dugas B, Fuentes M, Bertrand C.

J Immunol. 2000 Aug 1;165(3):1526-33.

45.

Fas-induced death of a murine pulmonary epithelial cell line: modulation by inflammatory cytokines.

Trifilieff A, Futjitani Y, Coyle AJ, Bertrand C.

Fundam Clin Pharmacol. 1999;13(6):656-61.

PMID:
10626753
46.

Endothelin receptor antagonists inhibit antigen-induced lung inflammation in mice.

Fujitani Y, Trifilieff A, Tsuyuki S, Coyle AJ, Bertrand C.

Am J Respir Crit Care Med. 1997 Jun;155(6):1890-4.

PMID:
9196091
47.

Activation of the Fas receptor on lung eosinophils leads to apoptosis and the resolution of eosinophilic inflammation of the airways.

Tsuyuki S, Bertrand C, Erard F, Trifilieff A, Tsuyuki J, Wesp M, Anderson GP, Coyle AJ.

J Clin Invest. 1995 Dec;96(6):2924-31.

48.

Effects of WIN 64338, a nonpeptide bradykinin B2 receptor antagonist, on guinea-pig trachea.

Scherrer D, Daeffler L, Trifilieff A, Gies JP.

Br J Pharmacol. 1995 Aug;115(7):1127-8.

49.

Bradykinin-induced contraction of human peripheral airways mediated by both bradykinin B2 and thromboxane prostanoid receptors.

Trifilieff A, Gies JP.

Am J Respir Crit Care Med. 1995 May;151(5):1687-8. No abstract available.

PMID:
7735635
50.

Structural requirements for neuropeptide Y in mast cell and G protein activation.

Mousli M, Trifilieff A, Pelton JT, Gies JP, Landry Y.

Eur J Pharmacol. 1995 Mar 15;289(1):125-33.

PMID:
7540143

Supplemental Content

Loading ...
Support Center